Hikma delivers a resilient underlying performance in 2022

Hikma delivers a resilient underlying performance in 2022

Amman, Jordan: – Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its preliminary audited results for the year ended 31 December 2022.

In 2022, the Group reported revenue of $2.517 billion (slightly down from $2.553 billion in 2021), backed by its resilient business model and good performance from the Injectables and Branded businesses, and offset by the effect of severe competitive pressures in the Generics business in the US and foreign exchange headwinds in the MENA region.

Benefitting from the Group’s healthy balance sheet, Hikma continued to invest 6% of revenue in R&D, supporting a growing pipeline of complex and specialty products. During 2022, Hikma had 182 new launches and received 270 approvals. To ensure the continuous development of the Group’s product pipeline, Hikma submitted 349 regulatory filings during the year.

Injectables business revenue up 8% in 2022, 10% in constant currency, to $1.141 billion ($1.053 billion in 2021), driven by acquisitions, new product launches and expansion into new geographies and partnerships. Injectables core operating profit increased by 8% with a core operating margin of 37.5%.

During the year, we successfully completed and integrated the acquisitions of Custopharm Inc. in the US and Teligent’s assets in Canada, and signed further